TrialNature communications2023

Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial.

Yabing Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.